Is Hester Biosciences a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Hester Biosciences Ltd is a good quality company .

Is Hester Biosciences undervalued or overvalued?

The key valuation ratios of Hester Biosciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Hester Biosciences share price return in the past 10 years?

Hester Biosciences Ltd share price has appreciated 20.9% annually (CAGR) over the past ten years.

Is Hester Biosciences a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Hester Biosciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

Hester Biosciences Ltd - Stock Valuation and Financial Performance

Name: Hester Biosciences
Brand: Hester Biosciences

BSE: 524669 | NSE: HESTERBIO | Pharmaceuticals & Drugs | Small Cap

Place order

Hester Biosciences Share Price

₹2,342 -43.10 -1.81%
as on 31-Oct'24 16:01

10 Year X-Ray of Hester Biosciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	19.9%	21.8%	24.2%	26.3%	31.2%	19.7%	23.3%	17.3%	11.9%	9.3%	-
Value Creation Index ⓘ	0.4	0.6	0.7	0.9	1.2	0.4	0.7	0.2	-0.2	-0.3	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	90	101	123	135	171	169	208	219	254	285	285
Sales YoY Gr.	-	12.1%	22.2%	9.3%	27%	-1%	23.1%	5.2%	15.8%	12.3%	-
Adj EPS ⓘ	14.2	22.8	29.3	35.8	50.9	35.7	51.6	45.4	36.9	31.5	37.2
YoY Gr.	-	60.9%	28.7%	22%	42.4%	-29.8%	44.3%	-11.9%	-18.7%	-14.6%	-
BVPS (₹) ⓘ	99	117.9	143.5	171.7	210.9	238.7	279.3	315.5	343.7	367.6	382.5
Adj Net Profit ⓘ	12	19.4	24.9	30.4	43.3	30.4	43.9	38.6	31.4	26.8	32
Cash Flow from Ops. ⓘ	20.4	18.6	27.6	32.3	36.2	25.8	41.1	15.9	33.4	42.8	-
Debt/CF from Ops. ⓘ	1.9	2.1	1.4	1.3	1.1	1.9	0.4	7.7	4.9	3.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	13.7%	10.7%	11%	12.3%
Adj EPS ⓘ	9.3%	-9.1%	-15.1%	-14.6%
BVPSⓘ	15.7%	11.8%	9.6%	7%
Share Price	20.9%	7.6%	-1.3%	41.4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	15	21	22.4	22.7	26.6	15.9	19.9	15.3	11.2	8.9	9.9
Op. Profit Mgn % ⓘ	28.5	33.4	33.4	36.8	39.7	31.1	34.7	27.6	21.5	16.4	18.3
Net Profit Mgn % ⓘ	13.4	19.2	20.2	22.6	25.3	18	21	17.6	12.4	9.4	11.1
Debt to Equity ⓘ	0.5	0.4	0.3	0.3	0.2	0.2	0.1	0.5	0.6	0.4	0.2
Working Cap Days ⓘ	231	229	217	220	208	261	245	279	292	271	128
Cash Conv. Cycle ⓘ	163	160	140	140	134	164	145	164	168	151	63

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 11.00%

Return on Equity has declined versus last 3 years average to 9.90%

Net Profit has been subdued in last 3 years -15.12%

Sales growth is not so good in last 4 quarters at 3.67%

Latest Financials - Hester Biosciences Ltd.

	Standalone	Consolidated
TTM EPS (₹)	37.2	27.6
TTM Sales (₹ Cr.)	285	312
BVPS (₹.) ⓘ	382.5	354.8
Reserves (₹ Cr.) ⓘ	317	293
P/BV ⓘ	6.13	6.61
PE ⓘ	63.02	85.05

From the Market
52 Week Low / High (₹)	1292.90 / 3375.45
All Time Low / High (₹)	0.25 / 3375.45
Market Cap (₹ Cr.)	1,996
Equity (₹ Cr.)	8.5
Face Value (₹)	10
Industry PE ⓘ	46.8

Management X-Ray of Hester Biosciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Hester Biosciences

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Hester Biosciences

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	90	101	123	135	171	169	208	219	254	285
Operating Expenses ⓘ	64	67	82	85	103	117	136	159	199	238
Manufacturing Costs	14	14	12	15	18	19	18	19	20	28
Material Costs	25	20	30	23	29	29	53	64	80	100
Employee Cost	12	15	18	22	27	37	33	39	48	57
Other Costs ⓘ	14	19	22	25	29	32	32	37	51	54
Operating Profit ⓘ	26	33	41	50	68	53	72	61	55	47
Operating Profit Margin (%)	28.5%	33.1%	33.3%	36.8%	39.6%	31.1%	34.5%	27.6%	21.5%	16.4%
Other Income ⓘ	0	1	1	2	3	3	2	5	6	5
Interest ⓘ	4	4	3	2	4	5	4	2	6	5
Depreciation ⓘ	5	6	6	5	8	9	10	10	10	10
Exceptional Items ⓘ	3	0	0	0	0	0	-5	0	0	0
Profit Before Tax ⓘ	19	25	33	44	60	41	55	53	44	37
Tax ⓘ	5	6	8	13	16	10	15	14	12	10
Profit After Tax	14	19	25	31	44	31	40	40	32	27
PAT Margin (%)	15.5%	19.1%	20.2%	22.7%	25.6%	18.4%	19.1%	18.0%	12.7%	9.5%
Adjusted EPS (₹)	16.5	22.6	29.3	35.9	51.6	36.7	46.9	46.5	38.0	31.9
Dividend Payout Ratio (%)	19%	18%	18%	28%	21%	18%	21%	22%	21%	19%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	84	100	122	146	179	203	238	268	292	313
Share Capital ⓘ	9	9	9	9	9	9	9	9	9	9
Reserves ⓘ	76	92	114	138	171	195	229	260	284	304
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	36	34	36	39	32	39	4	107	141	109
Long Term Debt	15	13	19	15	11	7	3	73	83	79
Short Term Debt	20	21	18	24	21	32	2	33	57	30
Trade Payables	5	6	7	8	8	14	14	11	29	30
Others Liabilities ⓘ	16	19	13	18	20	21	26	38	84	98
Total Liabilities ⓘ	140	159	178	210	240	277	282	424	546	550
Fixed Assets
Gross Block	94	105	110	121	162	167	165	171	199	204
Accumulated Depreciation	38	43	49	54	61	70	78	87	91	100
Net Fixed Assetsⓘ	57	62	61	67	101	97	87	84	108	103
CWIP ⓘ	14	10	21	30	0	1	4	82	149	171
Investmentsⓘ	9	9	9	14	28	41	44	65	65	65
Inventories	29	34	33	39	48	60	57	71	79	69
Trade Receivables	18	26	27	32	33	45	46	57	82	86
Cash Equivalents	4	5	11	12	2	5	1	2	6	5
Others Assetsⓘ	9	13	16	16	27	28	44	64	57	51
Total Assets ⓘ	140	159	178	210	240	277	282	424	546	550

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	20	19	28	32	36	26	41	16	33	43
PBT ⓘ	19	25	33	44	60	41	55	53	44	37
Adjustment ⓘ	7	9	9	7	8	12	20	12	15	13
Changes in Working Capital ⓘ	-0	-10	-7	-9	-16	-16	-20	-33	-17	4
Tax Paid ⓘ	-5	-6	-7	-9	-16	-11	-13	-16	-8	-11
Cash Flow From Investing Activity ⓘ	-12	-6	-15	-26	-25	-21	-4	-111	-72	-21
Capex	-8	-6	0	-21	-12	-7	-4	-90	-73	-22
Net Investments	0	0	0	0	-1	-2	1	-20	0	0
Others ⓘ	-4	0	-16	-5	-12	-12	-1	0	0	2
Cash Flow From Financing Activityⓘ	-5	-12	-6	-6	-20	-1	-41	95	41	-24
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	8	-2	6	-4	-3	-1	-2	73	12	-3
Interest Paid ⓘ	-4	-4	-3	-2	-4	-4	-4	-1	-10	-13
Dividend Paid ⓘ	-2	-5	-4	-6	-10	-7	-6	-9	-9	-7
Others ⓘ	-7	-1	-4	7	-3	11	-30	32	48	-2
Net Cash Flow ⓘ	3	1	6	0	-9	3	-4	0	3	-2

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	17.47	20.83	22.43	22.79	26.94	16.33	18.11	15.62	11.53	8.98
ROCE (%)	19.85	21.79	24.16	26.28	31.15	19.74	23.28	17.31	11.91	9.26
Asset Turnover Ratio	0.69	0.69	0.74	0.7	0.76	0.65	0.75	0.63	0.53	0.52
PAT to CFO Conversion(x)	1.43	1	1.12	1.03	0.82	0.84	1.03	0.4	1.03	1.59
Working Capital Days
Receivable Days	63	78	77	79	69	83	79	85	99	108
Inventory Days	128	111	97	97	93	117	103	105	107	94
Payable Days	67	97	81	120	99	135	94	72	91	108

Hester Biosciences Ltd Stock News

Hester Biosciences Ltd FAQs

What is the share price of Hester Biosciences?

Company share prices are keep on changing according to the market conditions. The closing price of Hester Biosciences on 31-Oct-2024 16:01 is ₹2,342.

What is the market cap of Hester Biosciences?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Oct-2024 16:01 the market cap of Hester Biosciences stood at ₹1,996.1.

What is the P/E ratio of Hester Biosciences?

The latest P/E ratio of Hester Biosciences as of 31-Oct-2024 16:01 is 63.02.

What is the P/B ratio of Hester Biosciences?

The latest P/B ratio of Hester Biosciences as of 31-Oct-2024 16:01 is 6.13.

What is the 52-week high and low of Hester Biosciences?

The 52-week high of Hester Biosciences is ₹3,375.5 and the 52-week low is ₹1,292.9.

What is the TTM revenue of Hester Biosciences?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Hester Biosciences is ₹285.4 ( Cr.) .

About Hester Biosciences Ltd

Hester Biosciences was incorporated on April 29, 1987 as a Private Limited Company by the name of Hester Pharmaceuticals Limited. It was subsequently converted into a Public Limited Company on November 1, 1993. The company is engaged in the manufacturing of poultry vaccines. The company has been promoted by Rajiv D. Gandhi his brother Sanjiv D. Gandhi and Dr. Bhupendra V. Gandhi. The company changed its name to the present in 2008.

The company is a 100% biotech company producing animal biologicals. Located near the city of Ahmedabad, in the state of Gujarat, in Western India, Hester has a state-of-the-art facility to produce live and killed (Inactivated) veterinary vaccines.

Production procedures for poultry vaccines based on in-house advanced capabilities are being followed in the areas of virus propagation in specific pathogen-free embryos, tissue culture, batch fermentation of bacteria, lyophilisation and emulsion preparation.

Hester on December 22, 2008 launched a poultry vaccine against Coryza disease in chicken, containing 3 serotypes â€“ A, B & C.

Hester is the first company in India to manufacture the Coryza vaccine with 3 strains as against other companies manufacturing the vaccine with only 2 serotypes - A & C. Coryza disease is of economical importance to poultry farmers as it causes a drop in egg production in laying birds.

Hester currently manufactures 39 types of poultry vaccines against various poultry diseases.

Product range of the company includes: